A class action lawsuit was filed last month in Canada alleging that Bayer, the maker of Trasylol, failed to warn about the increased risks of the drug, which is used during open heart surgery to reduce blood loss. As you will recall, a new study found the increased risks. Trasylol, or aprotinin, is injected during open heart surgery to reduce blood loss but has been linked to renal failure, heart attacks, strokes and other risks.
Over 4.5 million patients worldwide are estimated to have been given Trasylol before sales were suspended by the FDA in November 2007. We reported recently that about 150 Trasylol suits have been filed in the U.S., and there likely will be many more in the coming months. If you need additional information on the Trasylol litigation, contact Frank Woodson with our firm at 800-898-2034.
Source: Lawyers USA
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.